Equity Analysis /
United States of America

US : Johnson & Johnson - RJ Express: Publication of Phase 1/2 Data Adds Focus Back to Vaccine Opportunity

    CGS-CIMB
    14 January 2021
    Published byCGS-CIMB

    Full Phase 1/2a data published in NEJM: On Wednesday night, data from J&J's Phase 1/2a COVID trial were published in the New England Journal of Medicine . The data confirmed the safety and immunogenic response shown in the interim analysis that was released in Sep before the start of the Phase